Related Experiment Videos
Gemcitabine: a pharmacologic and clinical overview.
1Oncology Consulting Services Boston, Massachusetts, USA.
Cancer Nursing
|April 27, 1999
Summary
Gemcitabine is an effective antimetabolite chemotherapy drug for various cancers, including pancreatic cancer. It shows anticancer activity with a manageable safety profile, making it a valuable treatment option.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gemcitabine (GemzarR) is an FDA-approved antimetabolite for pancreatic cancer.
- It is a nucleoside analog with a unique mechanism of action.
- Demonstrated anticancer activity across multiple cancer types.
Purpose of the Study:
- Provide an overview of gemcitabine's pharmacology.
- Discuss innovative clinical trial endpoints, specifically clinical benefits response (CBR).
- Detail gemcitabine's clinical performance and required nursing care.
Main Methods:
- Review of clinical studies and trials involving gemcitabine.
- Analysis of gemcitabine's efficacy in various solid tumors.
- Evaluation of the clinical benefits response (CBR) as a novel endpoint.
Main Results:
- Gemcitabine exhibits anticancer activity in pancreatic, lung, breast, bladder, and ovarian cancers.
- Clinical benefits response (CBR) assesses performance status, pain, and weight gain.
- Myelosuppression is the primary dose-limiting toxicity, with a generally mild safety profile.
Conclusions:
- Gemcitabine is a significant chemotherapeutic agent with broad-spectrum anticancer properties.
- The CBR endpoint offers a comprehensive measure of treatment benefit in pancreatic cancer.
- Oncology nurses require specific knowledge for effective patient care with gemcitabine.